Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children

Antimicrob Agents Chemother. 2000 May;44(5):1375-6. doi: 10.1128/AAC.44.5.1375-1376.2000.


The bioavailability of didanosine at 180 mg/m(2) once daily was compared to that at 90 mg/m(2) twice daily in 24 children with advanced human immunodeficiency virus infection. Children were studied at steady state using optimal sampling and prior pharmacokinetic parameter estimates. Relative bioavailability was 0. 95 +/- 0.49, supporting the potential clinical adequacy of once-daily dosing.

MeSH terms

  • Anti-HIV Agents / pharmacokinetics*
  • Biological Availability
  • Child
  • Child, Preschool
  • Didanosine / pharmacokinetics*
  • HIV Infections / metabolism*
  • Humans


  • Anti-HIV Agents
  • Didanosine